Symbols / PRAX $293.75 -3.18%
PRAX Chart
About
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.18B |
| Enterprise Value | 7.85B | Income | -303.27M | Sales | — |
| Book/sh | 34.85 | Cash/sh | 21.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 168 | IPO | — |
| P/E | — | Forward P/E | -33.98 | PEG | — |
| P/S | — | P/B | 8.43 | P/C | — |
| EV/EBITDA | -24.08 | EV/Sales | — | Quick Ratio | 10.03 |
| Current Ratio | 10.22 | Debt/Eq | 0.01 | LT Debt/Eq | — |
| EPS (ttm) | -13.47 | EPS next Y | -8.65 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-30 | ROA | -28.69% |
| ROE | -45.83% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 27.85M |
| Shs Float | 25.78M | Short Float | 13.61% | Short Ratio | 8.02 |
| Short Interest | — | 52W High | 356.00 | 52W Low | 26.70 |
| Beta | 3.01 | Avg Volume | 507.81K | Volume | 94.90K |
| Target Price | $617.62 | Recom | Strong_buy | Prev Close | $303.38 |
| Price | $293.75 | Change | -3.18% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$617.63
Mean price target
2. Current target
$293.00
Latest analyst target
3. DCF / Fair value
$-94.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$293.00
Low
$130.00
High
$1245.00
Mean
$617.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Outperform | $500 |
| 2026-02-20 | main | Wells Fargo | Equal-Weight → Equal-Weight | $305 |
| 2026-02-20 | main | Baird | Outperform → Outperform | $433 |
| 2026-02-20 | main | Truist Securities | Buy → Buy | $700 |
| 2026-02-20 | main | Wedbush | Underperform → Underperform | $130 |
| 2026-02-10 | main | Guggenheim | Buy → Buy | $800 |
| 2026-02-04 | main | Needham | Buy → Buy | $510 |
| 2026-02-02 | init | Wells Fargo | — → Equal-Weight | $282 |
| 2026-01-30 | main | HC Wainwright & Co. | Buy → Buy | $1245 |
| 2026-01-28 | main | Piper Sandler | Overweight → Overweight | $1200 |
| 2026-01-12 | main | Wedbush | Underperform → Underperform | $95 |
| 2025-12-29 | main | BTIG | Buy → Buy | $843 |
| 2025-12-15 | main | Oppenheimer | Outperform → Outperform | $750 |
| 2025-12-09 | main | Jefferies | Buy → Buy | $450 |
| 2025-12-09 | main | Guggenheim | Buy → Buy | $760 |
| 2025-12-08 | main | TD Cowen | Buy → Buy | $353 |
| 2025-12-08 | main | Truist Securities | Buy → Buy | $500 |
| 2025-12-08 | main | Needham | Buy → Buy | $315 |
| 2025-12-08 | reit | HC Wainwright & Co. | Buy → Buy | $340 |
| 2025-12-08 | main | BTIG | Buy → Buy | $507 |
- Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance Sun, 15 Mar 2026 12
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - The Globe and Mail Wed, 18 Mar 2026 17
- Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN Wed, 18 Mar 2026 02
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool Mon, 16 Mar 2026 23
- Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat ue, 17 Mar 2026 07
- Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA Filings - Has The Bull Case Changed? - simplywall.st Sun, 15 Mar 2026 12
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com Mon, 16 Mar 2026 22
- This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget Mon, 16 Mar 2026 22
- Biotech Praxis gives 2,931 stock units to 14 new employees - Stock Titan Wed, 04 Mar 2026 21
- Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Yahoo Finance Wed, 18 Mar 2026 00
- Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - The Motley Fool Fri, 13 Mar 2026 15
- HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat Mon, 16 Mar 2026 11
- A Look At Praxis Precision Medicines (PRAX) Valuation After New Driehaus Investment And Recent FDA Filings - simplywall.st Fri, 13 Mar 2026 18
- Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc. - MarketBeat Sat, 14 Mar 2026 07
- PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Yahoo Finance Mon, 08 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1166 | — | — | Stock Award(Grant) at price 0.00 per share. | KINDLER JEFFREY B | Director | — | 2026-02-06 00:00:00 | D |
| 1 | 1166 | — | — | Stock Award(Grant) at price 0.00 per share. | ARBUCKLE STUART A | Director | — | 2026-02-06 00:00:00 | D |
| 2 | 27640 | — | — | Stock Award(Grant) at price 0.00 per share. | SOUZA MARCIO SILVA DE | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 9625 | — | — | Stock Award(Grant) at price 0.00 per share. | SNIECINSKI MEGAN | Chief Operating Officer | — | 2026-01-08 00:00:00 | D |
| 4 | 3750 | — | — | Stock Award(Grant) at price 0.00 per share. | MASTROCOLA LAUREN | Officer | — | 2026-01-08 00:00:00 | D |
| 5 | 6875 | — | — | Stock Award(Grant) at price 0.00 per share. | NEMIROFF ALEX | General Counsel | — | 2026-01-08 00:00:00 | D |
| 6 | 8800 | — | — | Stock Award(Grant) at price 0.00 per share. | KELLY TIMOTHY EDWIN | Chief Financial Officer | — | 2026-01-08 00:00:00 | D |
| 7 | 400 | — | — | Stock Gift at price 0.00 per share. | SOUZA MARCIO SILVA DE | Chief Executive Officer | — | 2025-12-30 00:00:00 | I |
| 8 | 13600 | 831257 | — | Conversion of Exercise of derivative security at price 43.37 - 133.65 per share. | MASTROCOLA LAUREN | Officer | — | 2025-11-20 00:00:00 | D |
| 9 | 25130 | 1853531 | — | Conversion of Exercise of derivative security at price 44.40 - 133.65 per share. | NEMIROFF ALEX | General Counsel | — | 2025-11-20 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -326.06M | -199.81M | -125.94M | -214.57M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -303.27M | -182.82M | -123.28M | -214.03M |
| ReconciledDepreciation | 140.00K | 358.00K | 432.00K | 419.00K |
| EBITDA | -326.06M | -199.81M | -125.94M | -214.57M |
| EBIT | -326.20M | -200.16M | -126.37M | -214.99M |
| NormalizedIncome | -303.27M | -182.82M | -123.28M | -214.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -303.27M | -182.82M | -123.28M | -214.03M |
| TotalExpenses | 326.20M | 208.72M | 128.82M | 214.99M |
| TotalOperatingIncomeAsReported | -326.20M | -200.16M | -126.37M | -214.99M |
| DilutedAverageShares | 17.91M | 6.59M | 3.07M | 2.83M |
| BasicAverageShares | 17.91M | 6.59M | 3.07M | 2.83M |
| DilutedEPS | -10.21 | -18.69 | -69.60 | -59.10 |
| BasicEPS | -10.21 | -18.69 | -69.60 | -59.10 |
| DilutedNIAvailtoComStockholders | -303.27M | -182.82M | -123.28M | -214.03M |
| NetIncomeCommonStockholders | -303.27M | -182.82M | -123.28M | -214.03M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -303.27M | -182.82M | -123.28M | -214.03M |
| NetIncomeIncludingNoncontrollingInterests | -303.27M | -182.82M | -123.28M | -214.03M |
| NetIncomeContinuousOperations | -303.27M | -182.82M | -123.28M | -214.03M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -303.27M | -182.82M | -123.28M | -214.03M |
| OtherIncomeExpense | 22.93M | 17.35M | 3.10M | 957.00K |
| OtherNonOperatingIncomeExpenses | 22.93M | 17.35M | 3.10M | 957.00K |
| OperatingIncome | -326.20M | -200.16M | -126.37M | -214.99M |
| OperatingExpense | 326.20M | 208.72M | 128.82M | 214.99M |
| ResearchAndDevelopment | 267.12M | 152.41M | 86.77M | 155.04M |
| SellingGeneralAndAdministration | 59.08M | 56.30M | 42.05M | 59.95M |
| GeneralAndAdministrativeExpense | 59.08M | 56.30M | 42.05M | 59.95M |
| OtherGandA | 59.08M | 56.30M | 42.05M | 59.95M |
| TotalRevenue | 0.00 | 8.55M | 2.45M | 0.00 |
| OperatingRevenue | 0.00 | 8.55M | 2.45M | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 25.20M | 19.42M | 8.79M | 3.29M |
| ShareIssued | 25.20M | 19.42M | 8.79M | 3.29M |
| TotalDebt | 110.00K | 1.37M | 2.50M | 3.50M |
| TangibleBookValue | 878.14M | 445.45M | 69.67M | 76.11M |
| InvestedCapital | 878.14M | 445.45M | 69.67M | 76.11M |
| WorkingCapital | 551.14M | 366.82M | 69.13M | 76.50M |
| NetTangibleAssets | 878.14M | 445.45M | 69.67M | 76.11M |
| CapitalLeaseObligations | 110.00K | 1.37M | 2.50M | 3.50M |
| CommonStockEquity | 878.14M | 445.45M | 69.67M | 76.11M |
| TotalCapitalization | 878.14M | 445.45M | 69.67M | 76.11M |
| TotalEquityGrossMinorityInterest | 878.14M | 445.45M | 69.67M | 76.11M |
| StockholdersEquity | 878.14M | 445.45M | 69.67M | 76.11M |
| GainsLossesNotAffectingRetainedEarnings | 563.00K | 654.00K | 0.00 | -173.00K |
| OtherEquityAdjustments | 563.00K | 654.00K | -173.00K | -176.00K |
| RetainedEarnings | -1.14B | -836.74M | -653.92M | -530.64M |
| AdditionalPaidInCapital | 2.02B | 1.28B | 723.58M | 606.92M |
| CapitalStock | 15.00K | 14.00K | 13.00K | 5.00K |
| CommonStock | 15.00K | 14.00K | 13.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 59.77M | 37.66M | 18.28M | 39.02M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 110.00K | 2.53M | 4.68M |
| NonCurrentDeferredLiabilities | 0.00 | 1.16M | 2.18M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 1.16M | 2.18M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 110.00K | 1.37M | 2.50M |
| LongTermCapitalLeaseObligation | 0.00 | 110.00K | 1.37M | 2.50M |
| CurrentLiabilities | 59.77M | 37.55M | 15.75M | 34.34M |
| CurrentDeferredLiabilities | 0.00 | 1.39M | 2.82M | 0.00 |
| CurrentDeferredRevenue | 0.00 | 1.39M | 2.82M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 110.00K | 1.26M | 1.13M | 1.00M |
| CurrentCapitalLeaseObligation | 110.00K | 1.26M | 1.13M | 1.00M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 18.71M | 9.37M | 3.72M | 2.80M |
| PayablesAndAccruedExpenses | 40.95M | 26.93M | 9.52M | 27.72M |
| CurrentAccruedExpenses | 16.32M | 14.40M | 3.70M | 13.05M |
| Payables | 24.63M | 12.53M | 5.82M | 14.67M |
| AccountsPayable | 24.63M | 12.53M | 5.82M | 14.67M |
| TotalAssets | 937.91M | 483.11M | 87.95M | 115.13M |
| TotalNonCurrentAssets | 327.00M | 78.74M | 3.07M | 4.29M |
| OtherNonCurrentAssets | 416.00K | 416.00K | 416.00K | 472.00K |
| InvestmentsAndAdvances | 326.76M | 76.96M | 0.00 | |
| InvestmentinFinancialAssets | 326.76M | 76.96M | 0.00 | |
| AvailableForSaleSecurities | 326.76M | 76.96M | ||
| NetPPE | 239.00K | 1.36M | 2.65M | 3.87M |
| AccumulatedDepreciation | -1.50M | -1.36M | -1.00M | -572.00K |
| GrossPPE | 1.74M | 2.72M | 3.66M | 4.44M |
| OtherProperties | 415.00K | 359.00K | 359.00K | 309.00K |
| MachineryFurnitureEquipment | 1.23M | 1.23M | 1.23M | 1.23M |
| BuildingsAndImprovements | 92.00K | 1.13M | 2.06M | 2.90M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 610.91M | 404.37M | 84.88M | 110.84M |
| OtherCurrentAssets | 11.58M | 11.80M | 3.58M | 10.35M |
| PrepaidAssets | 10.35M | 11.50M | ||
| CashCashEquivalentsAndShortTermInvestments | 599.33M | 392.57M | 81.30M | 100.49M |
| OtherShortTermInvestments | 242.00M | 177.19M | 0.00 | 38.87M |
| CashAndCashEquivalents | 357.33M | 215.37M | 81.30M | 61.62M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -249.12M | -131.76M | -111.19M | -185.49M |
| RepurchaseOfCapitalStock | 0.00 | |||
| IssuanceOfCapitalStock | 690.99M | 512.00M | 91.59M | 9.56M |
| CapitalExpenditure | -56.00K | -50.00K | -444.00K | -1.05M |
| EndCashPosition | 357.75M | 215.79M | 81.72M | 62.03M |
| BeginningCashPosition | 215.79M | 81.72M | 62.03M | 139.72M |
| ChangesInCash | 141.96M | 134.07M | 19.68M | -77.69M |
| FinancingCashFlow | 702.17M | 514.32M | 91.87M | 10.46M |
| CashFlowFromContinuingFinancingActivities | 702.17M | 514.32M | 91.87M | 10.46M |
| NetOtherFinancingCharges | -2.09M | -308.00K | -137.00K | -522.00K |
| ProceedsFromStockOptionExercised | 13.27M | 2.63M | 416.00K | 1.43M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockPayments | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 690.99M | 512.00M | 91.59M | 9.56M |
| CommonStockIssuance | 690.99M | 512.00M | 91.59M | 9.56M |
| InvestingCashFlow | -311.15M | -248.49M | 38.95M | 96.89M |
| CashFlowFromContinuingInvestingActivities | -311.15M | -248.49M | 38.95M | 96.89M |
| NetInvestmentPurchaseAndSale | -311.09M | -248.49M | 39.00M | 97.33M |
| SaleOfInvestment | 312.72M | 123.03M | 39.00M | 180.35M |
| PurchaseOfInvestment | -623.81M | -371.52M | 0.00 | -83.02M |
| NetPPEPurchaseAndSale | -56.00K | 0.00 | -50.00K | -444.00K |
| PurchaseOfPPE | -56.00K | 0.00 | -50.00K | -444.00K |
| OperatingCashFlow | -249.07M | -131.76M | -111.14M | -185.04M |
| CashFlowFromContinuingOperatingActivities | -249.07M | -131.76M | -111.14M | -185.04M |
| ChangeInWorkingCapital | 22.68M | 10.92M | -14.03M | -1.78M |
| ChangeInOtherWorkingCapital | -2.55M | -2.45M | 5.06M | -41.00K |
| ChangeInOtherCurrentLiabilities | -1.26M | -1.13M | -1.00M | -811.00K |
| ChangeInPayablesAndAccruedExpense | 23.30M | 22.82M | -17.35M | -6.57M |
| ChangeInAccruedExpense | 11.20M | 16.11M | -8.50M | -10.46M |
| ChangeInPayable | 12.10M | 6.71M | -8.86M | 3.89M |
| ChangeInAccountPayable | 12.10M | 6.71M | -8.86M | 3.89M |
| ChangeInPrepaidAssets | 640.00K | -8.22M | 6.77M | 547.00K |
| OtherNonCashItems | 1.03M | 3.43M | 837.00K | 752.00K |
| StockBasedCompensation | 33.94M | 41.36M | 24.86M | 28.59M |
| AmortizationOfSecurities | -3.59M | -5.01M | 47.00K | 1.00M |
| DepreciationAmortizationDepletion | 140.00K | 358.00K | 432.00K | 419.00K |
| DepreciationAndAmortization | 140.00K | 358.00K | 432.00K | 419.00K |
| Depreciation | 140.00K | 358.00K | 432.00K | 419.00K |
| NetIncomeFromContinuingOperations | -303.27M | -182.82M | -123.28M | -214.03M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PRAX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|